Opthea (NASDAQ: OPT) is one of 227 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Opthea to similar businesses based on the strength of its dividends, institutional ownership, valuation, analyst recommendations, profitability, risk and earnings.
Institutional & Insider Ownership
13.1% of Opthea shares are held by institutional investors. Comparatively, 52.9% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 16.9% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a summary of recent recommendations and price targets for Opthea and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Opthea currently has a consensus price target of $33.60, suggesting a potential upside of 365.37%. As a group, “Biological products, except diagnostic” companies have a potential upside of 29.62%. Given Opthea’s stronger consensus rating and higher probable upside, equities analysts plainly believe Opthea is more favorable than its peers.
Valuation and Earnings
This table compares Opthea and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Opthea Competitors||$599.90 million||$26.82 million||35.90|
Opthea’s peers have higher revenue and earnings than Opthea. Opthea is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Opthea and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Opthea Company Profile
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Receive News & Ratings for Opthea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opthea and related companies with MarketBeat.com's FREE daily email newsletter.